Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Edible Vaccine Market Revenue Outlook: What CAGR Lies Ahead Through 2030?#_x000D_
The edible vaccine market has experienced robust growth in recent years. This market is projected to expand from $9.51 billion in 2025 to $10.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Historically, this expansion has been driven by advancements in genetic engineering techniques, early research focused on transgenic plants for vaccine production, the enlargement of public health immunization programs, increased funding for alternative vaccine platforms, and initial clinical validation studies._x000D_
_x000D_
The edible vaccine market size is anticipated to demonstrate significant expansion over the next few years. It is projected to reach $14.54 billion in 2030, growing at a compound annual growth rate (CAGR) of 8.9%. The projected increase during this period can be attributed to factors such as a rising demand for vaccination solutions that do not require needles, increased investments in edible vaccine clinical trials, the expansion of livestock immunization programs, a growing emphasis on ensuring global vaccine accessibility, and advancements in the pathways for regulatory approval. Significant trends expected during the forecast period involve enhancements in plant-based vaccine expression systems, an increasing focus on oral vaccine delivery methods, the expansion of models for low-cost vaccine production, intensified research into heat-stable vaccines, and strengthening collaborations between the biotech and agricultural sectors._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Edible Vaccine Market Growth Backed By Core Demand Fundamentals#_x000D_
The expanding occurrence of infectious diseases is anticipated to fuel the future expansion of the edible vaccine market. These illnesses arise when detrimental microorganisms, such as bacteria, viruses, fungi, or parasites, enter the body and multiply. The heightened spread of infectious diseases is largely attributable to factors like globalization, climate change, urbanization, and antibiotic resistance, which foster the emergence and dissemination of new pathogens. Edible vaccines offer a cost-effective and needle-free immunization method for these conditions, working by prompting immune responses through the consumption of genetically modified foods that generate antigens. As an illustration, data from March 2024 by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated a rise in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, showing an increase of 1,295 cases. Furthermore, the rate per 100,000 people climbed from 2.5 in 2022 to 2.9 in 2023. Consequently, the growing incidence of infectious diseases is a primary catalyst for the edible vaccine market’s growth. The increasing financial support for research and development is projected to drive forward the growth of the edible vaccine market. Research and development funding encompasses monetary allocations designated for systematic inquiry and experimental efforts aimed at discovering novel knowledge and creating innovative products or technologies. Governments are progressively investing more in R&D, acknowledging the crucial role of scientific advancements in tackling worldwide health issues and maintaining a competitive edge within biotechnology sectors. This enhanced research funding directly empowers scientists and pharmaceutical companies to undertake sophisticated investigations into edible vaccine formulation, conduct clinical trials, and scale up production methodologies. For instance, data from December 2024, published by the Office for National Statistics, a UK-based government agency, revealed that UK businesses invested $64.73 billion (£50.0 billion) in research and development (R&D) in 2023, representing a $1.83 billion (£1.4 billion) or 2.9% increase compared to 2022. Consequently, the growth of the edible vaccine market is being propelled by increased research and development funding._x000D_
_x000D_
#Edible Vaccine Market Segment Analysis Spotlighting Growth Areas#_x000D_
The edible vaccine market covered in this report is segmented – _x000D_
_x000D_
1) By Vaccine Type: Subunit Vaccines, Virus-Like Particle VLP Vaccines, Plant-Expressed Antigen Vaccines, Recombinant Protein Vaccines, Other Edible Vaccine Types_x000D_
2) By Source: Fruits, Vegetables, Cereal Grains, Legumes, Other Edible Plants_x000D_
3) By Route of Administration: Oral Fresh Plant Consumption, Oral Processed Edible Form Feed, Sublingual And Buccal Edible Extract-Based_x000D_
4) By Distribution Model: Public Health And Immunization Programs, Veterinary And Animal Health Programs, Direct Farm-Level Administration, Research And Academic Institutions_x000D_
5) By Application: Human Immunization, Veterinary Vaccines, Livestock, Poultry, Aquaculture Vaccines, Other Applications_x000D_
6) By End User: Adults, Pediatrics, Animals_x000D_
_x000D_
Subsegments:_x000D_
1) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugated Subunit Vaccines_x000D_
2) By Virus-Like Particle (VLP) Vaccines: Plant-Derived VLP Vaccines, Chimeric VLP Vaccines, Multi-Antigen VLP Vaccines_x000D_
3) By Plant-Expressed Antigen Vaccines: Fruit-Based Edible Vaccines, Vegetable-Based Edible Vaccines, Grain-Based Edible Vaccines, Legume-Based Edible Vaccines_x000D_
4) By Recombinant Protein Vaccines: Recombinant Bacterial Antigen Vaccines, Recombinant Viral Antigen Vaccines, Recombinant Parasitic Antigen Vaccines_x000D_
5) By Other Edible Vaccine Types: Oral Mucosal Immunity-Targeted Vaccines, Multi-Epitope Edible Vaccines, Combination Edible Vaccines_x000D_
_x000D_
#Edible Vaccine Market Growth Trends Reshaping The Competitive Landscape#_x000D_
Leading companies in the edible vaccine market are concentrating on developing innovative solutions, such as oral cholera vaccine (OCV), to address the global cholera crisis. An oral cholera vaccine (OCV) is a type of vaccine administered by mouth to prevent cholera, a severe diarrheal disease caused by the bacterium Vibrio cholerae. For instance, in August 2024, Bharat Biotech International Limited, an India-based biotechnology company, launched Hillchol, an oral cholera vaccine (OCV) with several notable features. This live-attenuated vaccine stimulates both systemic and mucosal immune responses, providing protection against cholera. Hillchol is distinguished by its ease of administration and does not require cold storage, making it ideal for use in resource-limited settings. Moreover, it offers long-lasting immunity with just a single dose._x000D_
_x000D_
#Edible Vaccine Market Industry Leaders And Competitive Landscape#_x000D_
Major companies operating in the edible vaccine market are Medicago Inc., Vaxart Inc., Vaxiion Therapeutics Inc., Mymetics Corporation, Profectus BioSciences Inc., GreenLight Biosciences Inc., Akston Biosciences Corporation, Icon Genetics GmbH, iBio Inc., Kentucky BioProcessing Inc., Fraunhofer USA Center for Molecular Biotechnology, Nomad Bioscience GmbH, Baiya Phytopharm Company Limited, Dow AgroSciences LLC, GenCure Biomanufacturing, Transgene SA, PlantForm Corporation, BioBetter Ltd., Moolec Science SA, Agrenvec SL _x000D_
_x000D_
#View The Full Edible Vaccine Market Report:#_x000D_
_x000D_
#Edible Vaccine Market Regional Analysis And Top Geography#_x000D_
North America was the largest region in the edible vaccine market in 2025. The regions covered in the edible vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
